Replies to post #413833 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Go look at journal policies. Journals on average allow abstracts at conferences prior to journal articles. They simply don’t want sharing of proprietary information like charts, graphs and similar interpretive discussion.

For Example:

Disclosure of results before publication
• Presentation of data at a scientific meeting, as a poster, abstract, orally, on a CD, or as an abstract on the web, or on a preprint server does not conflict with submission to the Lancet journals. As a member journal of the International Committee for Medical Journal Editors, The Lancet does not regard results that are posted in the same clinical trials registry in which primary registration resides as a previous publication, if the results are presented in the form of a brief structured abstract or table

[MI Dendream]

Impact Factor risen to 12 that is pretty high.

https://academic.oup.com/neuro-oncology/pages/About

How possibly could you present at the meeting of the Society of NeuroOncology and publish without breaking embargo policy?

I am not worried that they can publish. The question is whether or not NEJM or Lancet will accept them. The alternative is a pretty good option.

[skitahoe]

I certainly agree with you on the TLD statement being out, but their presentation at SNO will only be accepted if it has information that's not been previously released, so it should proceed the Journal presentation which should be more comprehensive than the conference presentation. This is a formula that both Journals and major conferences agree to, it doesn't violate what the Journals want.

I certainly don't know this will happen, but it seems logical that they'd plan it this way. We will know for certain in just over 2 weeks, if nothing is stated before. While Dr. Liau should have had the opportunity to present an Abstract early enough not to be considered a late breaker, I suppose that she, and the company, would have the choice of submitting an Abstract that is considered a late breaker, and therefore not revealed until the first day of the conference.

From a timing standpoint, I'd think the company would issue TLD and update Clinical Trials just prior to the quarterly, so they can discuss it at the quarterly and announce a presentation at SNO, if it is to be. If no such announcement is made it doesn't mean it can't happen, but these events should be less than a week apart, I don't know why they'd want to be secret about it at that point.

If I'm correct, NWBO's quarterly is due mid November. I believe they have the option to request an additional week, so it's possible they could hold the quarterly until after SNO without any penalty for doing so. Right now it's important to meet at least allowable limits so as to not miss requirements needed to move to a bigger exchange. If the company really wished to end the quiet period and open up, they could delay the week, then release the quarterly and conduct a quarterly webcast after the presentation at SNO, and they'd be able to discuss all that had been presented. I'm not saying that this is what they're doing, but if they did it would clearly be a well planned roll out of the information. A Journal presentation could follow within days.

Hope that all have a Happy Halloween, and that November is truly a month for all of us to remember and be well rewarded.

Gary